by The global viscosupplementation market size reach USD 4.84 billion in 2023 and is projected to be worth around USD 12.10 billion by 2033, growing at a CAGR of 9.60% from 2024 to 2033.
Key Points
- Asia Pacific led the market with largest revenue share of 47% in 2023.
- Europe is expected to witness notable growth in the foreseeable future.
- By product, the three-injection segment has held the largest revenue share of 45% in 2023.
- By product, the single injection segment is anticipated to showcase rising growth in the market over the forecasted years.
- By end use, the orthopedic clinic/ASC segment has contributed more than 64% of revenue share of 64% in 2023.
- By end use, the hospital segment is forecasted to grow rapidly in the market over the forecast period.
The viscosupplementation market focuses on treatments that involve the injection of hyaluronic acid (HA) into joints, particularly the knee, to alleviate pain and improve mobility in patients suffering from osteoarthritis (OA). This procedure aims to restore the viscoelastic properties of the synovial fluid, which is often degraded in OA patients. Viscosupplementation has gained popularity due to its minimally invasive nature and potential to delay more invasive procedures like knee replacement surgery. The market includes various HA products differing in molecular weight, origin, and administration schedules.
Get a Sample: https://www.precedenceresearch.com/sample/4368
Growth Factors
Several factors are driving the growth of the viscosupplementation market. First, the increasing prevalence of osteoarthritis, driven by aging populations and rising obesity rates, is creating a larger patient base. Additionally, the growing preference for non-surgical and minimally invasive treatments among patients and healthcare providers is boosting demand for viscosupplementation. Advances in HA formulations, such as longer-lasting and more effective products, are also enhancing market growth. Furthermore, increased awareness and acceptance of viscosupplementation as a viable treatment option, supported by favorable reimbursement policies in many regions, contribute significantly to market expansion.
Viscosupplementation Market Scope
| Report Coverage | Details |
| Viscosupplementation Market Size in 2023 | USD 4.84 Billion |
| Viscosupplementation Market Size in 2024 | USD 5.30 Billion |
| Viscosupplementation Market Size by 2033 | USD 12.10 Billion |
| Viscosupplementation Market Growth Rate | CAGR of 9.60% from 2024 to 2033 |
| Largest Market | Asia Pacific |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Segments Covered | Product, End-use, and Regions |
| Regions Covered | North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa |
Viscosupplementation Market Dynamics
Regional Insights
The viscosupplementation market exhibits significant regional variation. North America, particularly the United States, holds a major share due to the high prevalence of osteoarthritis, advanced healthcare infrastructure, and strong adoption of new medical technologies. Europe also represents a significant market, with countries like Germany, France, and the UK leading due to their robust healthcare systems and high awareness levels. In the Asia-Pacific region, the market is growing rapidly, driven by large aging populations in countries like Japan and China, increasing healthcare expenditure, and improving access to advanced treatments. Latin America and the Middle East & Africa are emerging markets, with growth fueled by improving healthcare facilities and increasing osteoarthritis awareness.
Opportunities
The viscosupplementation market presents several opportunities for growth and innovation. Development of new HA formulations with enhanced efficacy and longer duration of action can attract more patients and healthcare providers. Personalized medicine approaches, where treatments are tailored to individual patient needs, can further enhance treatment outcomes and market acceptance. Expanding the indications for viscosupplementation beyond knee osteoarthritis to other joints, such as the hip, shoulder, and ankle, offers significant market potential. Additionally, increasing focus on emerging markets, where the prevalence of osteoarthritis is rising, can provide substantial growth opportunities for market players.
Challenges
Despite its growth potential, the viscosupplementation market faces several challenges. High costs associated with HA injections can limit patient access, particularly in regions with less developed healthcare systems or insufficient insurance coverage. Variability in patient response to treatment and the need for repeated injections can also affect patient satisfaction and adherence. Furthermore, competition from alternative treatments, such as physical therapy, pain medications, and surgical options, poses a challenge. Regulatory hurdles and the need for extensive clinical evidence to support new product approvals and reimbursements can slow market entry for innovative products.
Read Also: Blue Hydrogen Market Size to Reach USD 22.27 Billion by 2033
Viscosupplementation Market Recent Developments
- In November 2022, Anika Therapeutics Inc., a leading joint preservation healthcare firm, successfully completed the phase-3 study for a single primary endpoint. This medication is particularly curated for those dealing with severe knee osteoarthritis. This enterprise is further focusing on achieving FDA approval for its medication and its clearance to use in the global market.
- In June 2022, Johnson and Johnson released new data from phase-3 trials showing patients treated with medications who have achieved better and more consistent long-term results through two years of dealing with active psoriatic arthritis.
Viscosupplementation Market Companies
- DePuy Synthes
- Fidia Farmaceutici S.p.A
- Sanofi
- Smith & Nephew PLC
- Anika Therapeutics, Inc.
- Seikagaku Corp.
- Zimmer Biomet
- Ferring Pharmaceuticals B.V.
- Lifecore Biomedical
- LG Life Sciences Ltd.
- F.Hoffmann-La Roche Ltd.
Segments Covered in the Report
By Product
- Single Injection
- Three Injection
- Five Injection
By End-use
- Hospitals
- Orthopaedic Clinics/ASCs
By Geography
- North America
- Asia Pacific
- Europe
- Latin America
- Middle East & Africa
Contact Us:
Mr. Alex
Sales Manager
Call: +1 9197 992 333
Email: sales@precedenceresearch.com
Web: https://www.precedenceresearch.com
Blog: https://www.expresswebwire.com/
Blog: https://www.uswebwire.com/
